News

PI Perspective: Notes From a U.K. Site Alliance Network Event

Luke Boylan, MBChB, MBA, Principal Investigator at Velocity in North London, recently attended the Parexel Site Alliance Network event. This collaborative gathering included NHS/NIHR-affiliated sites and other commercial research organizations, providing an invaluable opportunity to discuss the evolving landscape of clinical trials in the U.K. Dr. Boylan’s key takeaways from the event: Regulatory Improvements: There … Read more

Paul Evans Joins the Leaders & Legends Podcast With Patty Leuchten

Paul Evans sat down with Patricia Leuchten on the Leaders & Legends podcast, where they discussed the state of research sites and the broader industry. Listen now to hear Paul’s thoughts on:  The evolution of clinical research sites and what’s ahead for the industry.  Challenges in patient recruitment and the role of site-based technology.  His … Read more

Establishing Excellence With the Women’s Health CARE Council

Women’s health remains one of the most overlooked and underrepresented areas in clinical research, often leading to gaps in treatment and understanding. Similar to obesity research, disorders relating to reproductive health include symptoms that are highly stigmatized and patients can be reluctant to seek treatment or join clinical trials. This is why Velocity set up … Read more

Velocity Appoints Craig Koch to Lead European Expansion, Reinforcing Commitment to the Region

Craig Koch has been appointed as Velocity’s new Executive Vice President, Europe, to spearhead the next phase of growth across the region. His appointment underscores the company’s long-term commitment to Europe. Previously serving as EVP, Global Head of Sales, Craig has been with Velocity since 2019. He is now relocating to Europe to provide hands-on … Read more

Brandon Essink, MD, CPI, is Lead Author of a New Article in Vaccine

Brandon Essink, MD, CPI, is the lead author of study results exploring a next-generation flu vaccine for adults 50+. The published results highlight the potential for combining cell-based approaches and adjuvants to enhance immunogenicity relative to standard flu vaccines on the market. Title: “A randomised phase 2 immunogenicity and safety study of a MF59-adjuvanted quadrivalent … Read more

Velocity Nominated for Two 2025 Vaccine Industry Excellence (ViE) Awards

Velocity is a nominee for two 2025 Vaccine Industry Excellence (ViE) Awards! After winning the Best Clinical Trial Company ViE Award in 2024, we would be honored to receive your vote and once again share this recognition with you as we work to improve vaccine trials worldwide. Vote now: https://terrapinn-awards.evessiocloud.com/vieawards2025/en/page/public-vote-vie-awards We look forward to seeing … Read more

Velocity’s VISION Recognized at 2025 SCOPE Site Innovation Awards

Thank you to SCOPE Summit for recognizing Velocity at the 2025 Site Innovation Award presentation! Our presentation focused on the way VISION is enhancing trial accessibility for participants worldwide. Now available in four countries and four languages, the VISION Engage mobile app has been downloaded more than 100,000 times. To date, VISION has supported: • … Read more

Velocity Partners with Verified Clinical Trials to Combat Double Enrollment Problem in Clinical Trials

Velocity Clinical Research, the leading multi-specialty clinical research organization, has partnered with Verified Clinical Trials (VCT) to set a new benchmark for patient safety and data quality in clinical trials through a new technological implementation at Velocity’s 80+ global sites.  The collaboration addresses a critical industry challenge: the double enrollment of participants in multiple studies … Read more